Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Invested Capital (2021 - 2026)

Axsome Therapeutics' Invested Capital history spans 6 years, with the latest figure at $65.7 million for Q1 2026.

  • On a quarterly basis, Invested Capital fell 71.81% to $65.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $65.7 million, a 71.81% decrease, with the full-year FY2025 number at $208.3 million, down 12.12% from a year prior.
  • Invested Capital hit $65.7 million in Q1 2026 for Axsome Therapeutics, down from $208.3 million in the prior quarter.
  • Over the last five years, Invested Capital for AXSM hit a ceiling of $458.8 million in Q2 2023 and a floor of $64.7 million in Q1 2022.
  • Historically, Invested Capital has averaged $240.2 million across 5 years, with a median of $233.2 million in 2025.
  • Biggest five-year swings in Invested Capital: surged 316.34% in 2023 and later crashed 71.81% in 2026.
  • Tracing AXSM's Invested Capital over 5 years: stood at $204.6 million in 2022, then surged by 81.36% to $371.0 million in 2023, then crashed by 36.11% to $237.0 million in 2024, then decreased by 12.12% to $208.3 million in 2025, then crashed by 68.44% to $65.7 million in 2026.
  • Business Quant data shows Invested Capital for AXSM at $65.7 million in Q1 2026, $208.3 million in Q4 2025, and $193.7 million in Q3 2025.